Navigation Links
MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
Date:2/5/2008

Presentation will be webcast live and archived on Company's web site

GERMANTOWN, Md., Feb. 5 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that Dr. Edward M. Rudnic, MiddleBrook president and CEO, will deliver a corporate presentation on Monday, February 11, 2008, at 11:45 a.m. Eastern Time.

The presentation will take place as part of the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2008 at the Waldorf Astoria hotel in New York, New York. Dr. Rudnic's remarks will be available live on the MiddleBrook web site, where they also will be archived for 30 days.

To access the presentation, log on to http://www.middlebrookpharma.com and click on the Presentations option in the Investor Relations section. Please connect to the web site several minutes prior to the start of the live presentation to ensure adequate time for any software download that may be necessary.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.


'/>"/>
SOURCE MiddleBrook Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Anthera Pharmaceuticals Forms Scientific Advisory Board
5. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
6. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
10. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Access Pharmaceuticals Announces $2.7 Million New Equity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... ... Back pain relief technology is now available without a prescription at What ... relief for WAR members. , This spinal restoration platform boasts utilization of technology that ... suffering from chronic back pain. , What A Relief Back Pain Centers ...
(Date:1/11/2017)... , PITTSBURGH and BENGALURU, ... (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, ... Drug Administration (FDA) has accepted Mylan,s biologics license application ... through the 351(k) pathway. This product is a proposed ... certain HER2-positive breast cancers. The anticipated FDA goal date ...
(Date:1/11/2017)... , Jan. 11, 2017  GenVec, Inc. ... delivery company, announced today that its chief scientific ... a talk entitled  "AdenoVerse™ platform for translational development ... Biotech Showcase at the upcoming Phacilitate Cell & ... Miami , Florida.  Dr. Brough,s presentation will ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... signed a multi-year license agreement with Poseida Therapeutics Inc, the San Diego based ... genetic data. Poseida Therapeutics selected KBioBox in order to harness KBioBox’s powerful BioEngine ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):